![]() | ![]() |
Formats:
|
||||||||||||||||||
Copyright © 2008 Wang et al. Article AP-2 factors act in concert with Notch to orchestrate terminal differentiation in skin epidermis 1The Howard Hughes Medical Institute and Laboratory of Mammalian Cell Biology and Development, The Rockefeller University, New York, NY 10065 2Department of Craniofacial Biology and Cell and Developmental Biology, University of Colorado Health Sciences Center, Aurora, CO 80045 Correspondence to Elaine Fuchs: fuchslb/at/rockefeller.edu Received April 7, 2008; Accepted September 2, 2008. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jcb.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/). This article has been cited by other articles in PMC.Abstract The mechanisms by which mammalian epidermal stem cells cease to proliferate and embark upon terminal differentiation are still poorly understood. By conditionally ablating two highly expressed transcription factors, AP-2α and AP-2γ, we unmasked functional redundancies and discovered an essential role for AP-2s in the process. In vivo and in vitro, AP-2 deficiency is accompanied by surprisingly minimal changes in basal gene expression but severely perturbed terminal differentiation and suppression of additional transcription factors and structural genes involved. In dissecting the underlying molecular pathways, we uncover parallel pathways involving AP-2 and Notch signaling, which converge to govern CCAAT/enhancer binding protein genes and orchestrate the transition from basal proliferation to suprabasal differentiation. Finally, we extend the striking similarities in compromising either Notch signaling or AP-2α/AP-2γ in developing skin to that in postnatal skin, where all hair follicles and sebaceous gland differentiation are also repressed and overt signs of premalignant conversion emerge. Introduction In mouse, skin begins as a single layer of surface ectoderm from which the adult epidermis and its appendages develop. These cells are marked by expression of keratins 5 and 14 (K5 and K14; Byrne et al., 1994). As mesenchyme populates the skin, localized interactions occur, initiating specialized morphogenetic programs that lead to hair follicle (HF) morphogenesis and epidermal stratification. By embryonic day (E) 14.5, epidermis is two cell layers thick that are characterized by K5/K14 in the basal layer and K1/K10 in suprabasal (spinous) cells (Fuchs and Green, 1980; Byrne et al., 1994). By E16.5–17.5, several layers of spinous cells are capped by emergence of a morphologically distinct granular layer, marked by expression of late stage differentiation markers, including transglutaminases, loricrin, and filaggrin (Rothnagel et al., 1987). Just before birth, epidermal maturation concludes, as outermost cells lose their cellular organelles, transglutaminases are activated, and lipid bilayers are extruded to sandwich the dead stratum corneum layers. Postnatally, the stratum corneum provides a functional barrier to protect animals from dehydration and infection (Segre, 2006). Adult epidermis undergoes constant turnover and repair by maintaining within the basal layer a resident population of stem cells that are able to both proliferate and execute the suprabasal terminal differentiation program. Homeostasis is maintained by a continual flux of basal cells departing from their proliferative compartment, committing to terminally differentiate, moving outward, and being sloughed from the skin surface (Blanpain and Fuchs, 2006). The balance between epidermal growth and differentiation must be intricately controlled, and many key changes regulating this transition take place at the basal to suprabasal juncture. Transcription factors CCAAT/enhancer binding protein (C/EBP) α and β (Nerlov, 2007) as well as Notch receptor signaling have been implicated in governing cell fate within spinous cells (Maytin et al., 1999; Zhu et al., 1999; Dai and Segre, 2004; Okuyama et al., 2004; Blanpain et al., 2006). Since early discoveries of AP-2 transcription factor binding sites in promoters of many epidermally expressed genes, AP-2 proteins have been implicated in epidermal biology (Leask et al., 1990; Snape et al., 1991; Byrne et al., 1994; Zeng et al., 1997; Maytin et al., 1999; Sinha et al., 2000; Luo et al., 2002, 2005; Panteleyev et al., 2003; Vernimmen et al., 2003; Koster et al., 2006; Wang et al., 2006). The functions of AP-2α and AP-2γ have been postulated to be active in mouse surface ectoderm by E9.5, i.e., before K5 and K14 are induced (Byrne et al., 1994; Koster et al., 2006). How AP-2 proteins function in epidermis has been less clear, nor is much known about the regulation of these transcription factors. Both basal and suprabasal genes possess AP-2 binding sites, and both positive and negative activities have been observed in vitro, depending on the particular AP-2, gene, and cell type used in the study (Byrne et al., 1994; Sinha et al., 2000; Dai and Segre, 2004; Eckert et al., 2005; Koster et al., 2006; Nagarajan et al., 2008). To date, the best genetic evidence in support of a major role for AP-2s in vertebrate epidermal biology stems from AP-2 morpholino knockdowns in Xenopus laevis oocytes, where neurogenesis becomes promoted at the expense of epidermal fate (Luo et al., 2002). Difficulties in dissecting AP-2 functions in mammalian skin have been compounded by their broad expression and physiological importance to many tissues, often resulting in embryonic or early neonatal lethality when targeted for ablation. Individual conditional targeting of AP-2α and more recently AP-2γ, two abundantly expressed AP-2 family members in skin, has been only modestly informative. K14-Cre conditional targeting of AP-2α resulted in normal epidermal development (Wang et al., 2006), as expected because AP-2α null mice survive until birth (Zhang et al., 1996). Postnatally, epidermis lacking AP-2α also appeared morphologically normal, although a target gene, EGF receptor (EGFR), was elevated in spinous layers. Abnormalities were only unmasked when skin was stimulated by EGFR ligands, resulting in excessive localized hyperproliferation. Together, these results hinted that without AP-2α, even though epidermal development and homeostasis are maintained, the balance may be precarious (Wang et al., 2006). Similarly, Sox2-Cre ablation of AP-2γ resulted in a transient developmental delay in epidermal stratification, but by birth AP-2γ null epidermis appeared morphologically and biochemically normal (Guttormsen et al., 2008). Documentation and further dissection of the possible role for AP-2γ in epidermis were not possible because the mice had neural tube closure and osteogenesis defects and died soon after parturition. By conditionally removing functional redundancies of AP-2 family members in skin, we've now uncovered and characterized previously masked but critical functions of AP-2 transcription factors in epidermal differentiation and barrier function acquisition. Our findings provide major new insights to our understanding of AP-2 in skin development and differentiation and provide an unexpected link between Notch and AP-2s that governs in the early switch in epidermal terminal differentiation. Results Morphological and physiological defects in epidermis of mice lacking AP-2α and AP-2γ By microarray and real-time PCR, AP-2α and AP-2γ are the most abundantly expressed AP-2 genes in mouse skin (Wang et al., 2006). Antibodies monospecific for AP-2α and AP-2γ (Wang et al., 2006) localized these proteins to the nuclei of cells within basal and spinous layers (Fig. 1 A
Because AP-2s share a common DNA binding sequence and can operate as either hetero- or homodimers, the substantially overlapping expression patterns of AP-2α and AP-2γ raised the possibility that these two family members may at least partially overlap in their functions. To explore this possibility, we used K14-Cre, which is active in all skin epithelia with proliferative potential, to generate mice conditionally deleted for AP-2γ (Guttormsen et al., 2008). We then mated these mice to our previously generated K14-Cre/AP-2αlox/lox mice (Nelson and Williams, 2004; Wang et al., 2006) to produce mice with conditional loss of both AP-2 genes. As judged by immunodetection, immunoblot analyses, and real-time PCR, AP-2α and AP-2γ expression were efficiently extinguished in epidermis of newborn K14-Cre/AP-2αlox/loxAP-2γlox/lox double conditional knockout (DcKO) mice (Fig. 1, A and B As we had observed previously with AP-2α conditional knockout (cKO) mice (Wang et al., 2006), AP-2γ cKO animals developed normally (Fig. 1 C Histological analyses revealed additional abnormalities (Fig. 1 D Because animals deteriorated rapidly after birth, appeared to be severely dehydrated at death, and exhibited gross perturbations in terminal differentiation, we surmised that the barrier function might be compromised. As judged by dye exclusion assays, single cKO embryos paralleled the WT kinetics of barrier acquisition (Fig. 1 F Molecular defects in early terminal differentiation in epidermis lacking AP-2α and AP-2γ Further analyses revealed that abnormalities visible in newborn DcKO epidermis were already present in developing embryos. By E17.5, DcKO epidermis showed few signs of granular or stratum corneum formation, which contrasted markedly with either WT or single AP-2γ or AP-2α skins (Fig. 2 A
Analogous to the morphological defects, molecular deviations began at the basal to spinous transition and extended throughout metabolically active stages of terminal differentiation. DcKO epidermis displayed reduced immunolabeling for markers of both spinous (K1) and granular (involucrin and filaggrin) layers (Fig. 2 A In contrast to marked perturbations in terminal differentiating cells, the basal layer of DcKO embryos appeared largely unaffected morphologically and biochemically. K5/K14 was still mainly confined to the innermost basal layer, and K5/K14 mRNA levels appeared comparable between WT and DcKO embryonic skin (Fig. 2, A and B The consequences of AP-2α and AP-2γ loss in vivo were recapitulated when primary mouse epidermal keratinocytes (1°MK) were propagated in vitro. In low Ca2+ media, double knockout (DKO) and WT 1°MK expressed comparable levels of basal keratin mRNAs (Fig. 2 E When calcium levels were increased to promote terminal differentiation, differences in gene expression between DKO and WT 1°MK became profound (Fig. 2 F The molecular aberrations caused by loss of AP-2α and AP-2γ go beyond the normal program of epidermal terminal differentiation The biochemical changes observed upon loss of AP-2 proteins in epidermis went beyond perturbations in the normal program of terminal differentiation. Perhaps most striking in this regard was the aberrant expression of K8 protein and mRNA in suprabasal layers of DcKO embryonic skin (Fig. 3, A and B
In agreement with these data, K18, the normal periderm partner for K8, was not induced in DcKO spinous cells (Fig. S2 A, available at http://www.jcb.org/cgi/content/full/jcb.200804030/DC1), whereas K6 mRNA and protein were (Fig. 3, A and B In summary, loss of both AP-2α and AP-2γ unveiled marked defects in epidermal terminal differentiation that were hidden in singly targeted animals. Although otherwise largely unaffected, the hypoproliferation displayed by embryonic DcKO epidermis could contribute to the reduction in terminally differentiating layers of newborn epidermis. Repression of C/EBP transcription factors in part accounts for the marked defects arising from loss of AP-2α and AP-2γ The reduction in K10 mRNA was intriguing, given prior in vitro studies that implicated the C/EBPs in regulating K10 gene expression (Maytin et al., 1999) and in inducing K1 and K10 expression when overexpressed (Zhu et al., 1999). C/EBPα and C/EBPβ are both expressed in mouse epidermis and consensus binding sites for these factors have been identified in both K1 and K10 promoters (Mack et al., 2005). Given the surprising and global repression of terminal differentiation-specific genes resulting from dual loss of AP-2α and AP-2γ, we wondered whether the status of C/EBP expression might also be altered. To explore this possibility, we first used immunofluorescence microscopy with monospecific antibodies against C/EBPα and C/EBPβ (Fig. 4 A
These in vivo results were also corroborated with studies in vitro. As judged by immunoblot analyses of protein lysates from 1°MK cultured in the presence of low Ca2+, both isoforms of C/EBPα, Cα p42 and Cα p30 (Calkhoven et al., 2000), were barely detectable when AP-2α and AP-2γ were absent but readily detected in WT lysates (Fig. 4 B Real-time PCR revealed that the reduction in C/EBP proteins occurring upon loss of AP-2 factors was reflected at least in part at the mRNA level (Fig. 4 C Like C/EBP, AP-2 proteins have also been implicated in regulating terminal differentiation-specific genes (Snape et al., 1991; Luo et al., 2003, 2005). To dissect their relative importance, we therefore tested the consequences to two early terminal differentiation genes, K1 and K10, when AP-2 and C/EBP activities were independently restored in AP-2 DKO keratinocytes. For this purpose, we retrovirally infected cells with transgenes expressing either GFP (control vector) or, additionally, transcription factor AP-2α, C/EBPα, or C/EBPβ. Infected cells were enriched by FACS purification based on GFP positivity. The results of these experiments are shown in Fig. 4 D Defects in downstream effectors of Notch signaling in the absence of AP-2α and AP-2γ The marked defects in terminal differentiation that originated at the basal to spinous layer transition in mice lacking AP-2α and AP-2γ resembled that caused by loss of RBP/J, the obligate canonical Notch signaling partner (Blanpain et al., 2006). Given that Notch signaling is also known to play a key role not only in K1 and K10 expression but also in governing terminal differentiation (Lowell et al., 2000; Okuyama et al., 2004; Blanpain et al., 2006; Estrach et al., 2007), we wondered whether there might be a functional link between Notch signaling, AP-2 transcription, and induction of the terminal differentiation program in epidermal cells. To test this possibility, we transduced AP-2 DKO 1°MK with a retroviral vector encoding the Notch intracellular domain (NICD), which functions as a transcriptional coactivator for the RBP/J DNA binding protein (Artavanis-Tsakonas et al., 1999; Iso et al., 2003; Lai, 2004). As expected from prior studies with WT 1°MK (Okuyama et al., 2004; Blanpain et al., 2006), expression of NICD in our control (WT) cultures in low Ca2+ media (differentiation restricted) increased mRNA levels of K1 and K10 but not K14 (Fig. 5 A
To determine whether AP-2 might be required to mediate Notch signaling, we repeated the experiments, this time evaluating whether two NICD/RBP/J target genes (Hes1 and Hey1) known to be expressed in keratinocytes could be activated in the absence of AP-2. As shown in Fig. 5 B One possible explanation consistent with the results at hand is that Notch signaling is responsible for AP-2 expression, which would place AP-2s downstream of Notch. If so, then expression of NICD in low Ca2+ medium should result in elevated AP-2 mRNA levels in WT keratinocytes. Whereas NICD stimulated ~2.5-fold elevation in AP-2γ expression, AP-2α mRNA levels were relatively unaffected (Fig. 5 C To gain further insights into the relation between Notch signaling and AP-2s, we examined the consequences of RBP/J loss of function on AP-2 gene expression. Given the deleterious long-term effects of RBP/J ablation, we used a GFP-tagged adenovirus expressing Cre recombinase to target ablation in 1°MK cultures of RBP/Jlox/lox cells. 48 h after ablation, FACS was used to isolate Cre-infected cells by GFP positivity. Cre activity led to efficient ablation of RBP/J gene expression, as indicated by the corresponding down-regulation in K1 and Hes1 mRNAs in Cre-targeted RBP/Jlox/lox 1°MK (Fig. 5 D Notch signaling regulates expression of C/EBPα Given our identification of C/EBPs as downstream targets of AP-2 transcriptional activities, and based on our results thus far, we turned our attention to the possibility that canonical Notch signaling might contribute to epidermal differentiation by regulating C/EBP expression. To test this hypothesis, we examined the consequences of RBP/J ablation on C/EBPα mRNA levels. As shown in Fig. 6 A
These effects observed in vitro were recapitulated in vivo, as judged by both real-time PCR and immunoblot analyses of epidermal mRNAs and proteins, respectively, from E18.5 K14-Cre/RBP/Jlox/lox cKO (Fig. 6 D Finally, because full knockout of RBP/J blocks keratinocyte growth, we used lentivirus to express a short hairpin RNA (shRNA) that produced >60% of RBP/J mRNA inhibition in 1°MK. Interestingly, RBP/J knockdown resulted in a further reduction of C/EBPα mRNA expression in AP-2α/AP-2γ DKO cells (Fig. 6 F More parallels between Notch signaling and AP-2 transcription: hyperproliferation and squamous metaplasia in postnatal skin lacking AP-2α and AP-2γ Given the parallel and yet converging pathways of Notch signaling and AP-2 expression and the phenotypic similarities between conditionally targeted Notch and AP-2 loss-of-function mutations in skin development, we wondered whether this link might persist in adulthood. Previous studies on Notch signaling revealed that despite impaired epidermal proliferation in embryonic skin lacking RBP/J, engrafted postnatal skin is associated with hyperproliferation and impaired terminal differentiation (Blanpain et al., 2006). This is also seen when Notch is partially compromised in skin (Nicolas et al., 2003; Pan et al., 2004; Lee et al., 2007). To pursue this parallel further, we engrafted doubly targeted AP-2α and AP-2γ null skin to the backs of Nude mice. By 12–14 d after engraftment, WT skin grafts are typically in the final stages of recovering from a woundlike response, and by 21–45 d, grafts display normal epidermal homeostasis (Blanpain et al., 2004; Claudinot et al., 2005). Distinct from WT, DcKO grafts appeared rough and flaky, both at day 13 and 45 after grafting (Fig. 7 A
Whereas postnatal skin from mice singly targeted for AP-2γ appeared normal, we previously found that as mice that were singly targeted for AP-2α aged, they healed their wounds but displayed signs of epidermal hyperproliferation in mechanically traumatized skin regions (Wang et al., 2006). Because this was accompanied by elevated EGFR and Akt signaling (Wang et al., 2006), we tested and found similar up-regulation of this signaling pathway in the grafted DcKO skins (Fig. S4 A, available at http://www.jcb.org/cgi/content/full/jcb.200804030/DC1). The hyperproliferative epidermis of DcKO skin differed significantly from that of AP-2α cKO skin: it was uniform, rapidly developing, and sustained and exhibited K8 and other biochemical abnormalities found only upon additional targeting for AP-2γ (Fig. S4 B). When taken together, the most striking defect shared by both E17.5 and engrafted DcKO skin was the profound repression of terminal differentiation. Given this commonality, we surmise that the hyperproliferative state of the engrafted but not the E17.5 DcKO skin is likely secondary and attributable to an ill-fated rescue response to a defective epidermal barrier and terminal differentiation program. That said, it is also possible that AP-2s and Notch play dual roles in epidermal proliferation and differentiation, acting to promote either event depending on cellular context. Klf4 is an example of a transcription factor with such dual roles, acting as either tumor suppressor or oncogene depending on context (Rowland and Peeper, 2006). Defects in HF differentiation in AP-2α and AP-2γ DcKO skin A final similarity between loss of AP-2 factors versus RBP/J came from examining the consequences of gene targeting to HF differentiation. Loss of AP-2s did not appear to affect overall numbers of HFs. Moreover, E18.5 DcKO guard HFs still expressed markers of HF maturation: companion layer (K6+), IRS (Gata3+), and hair shaft precursor (AE15+; Fig. S2 B and Fig. S4, D and F). That said, guard hair development initiates early and perhaps precedes strong K14 promoter activity (Vasioukhin et al., 1999). In contrast, newborn DcKO animals did not form visible whiskers (Fig. 1 C To explore further the possible importance of AP-2s in HF differentiation, we engrafted E18.5 skins onto the backs of Nude mice immunocompromised and defective in HF morphogenesis. In WT grafts, hair formation was already visible at day 13, when the bandages were removed. In contrast, DcKO grafts displayed no visible hairs even 45 d after grafting (Fig. 7 A Discussion Dissecting how AP-2 functions in epidermal biology has awaited unmasking the layers of functional redundancy that are caused by the multiplicity of AP-2 factors expressed in skin. By conditionally targeting the two most abundantly expressed AP-2 genes, we've discovered that AP-2 factors play a prominent role in the master regulatory switch at the basal–suprabasal juncture. The central participation of AP-2 transcription in the molecular trigger that coaxes basal epidermal cells to initiate terminal differentiation adds a newfound physiologically significance to this family of transcription factors in epidermal development and homeostasis. The additional marked defects in sebaceous gland and HF differentiation that arise from loss of AP-2α and AP-2γ further unveil and expand the importance of these proteins in repressing multiple differentiation lineages within the skin. Surprisingly, despite striking perturbations in terminal differentiation-specific gene expression arising from loss of AP-2α and AP-2γ, we did not observe marked alterations in basal gene expression at least in development and homeostasis. This was both surprising and unexpected based on single AP-2α or AP-2γ null phenotypes and on the presence of functional AP-2 sites within the K14 and K5 promoters (Leask et al., 1990; Byrne et al., 1994; Sinha et al., 2000). It is possible that other AP-2 family members expressed in skin might function in regulating basal fate (Sinha et al., 2000). Additionally, based on our discovery that K14/K5 is expanded suprabasally in engrafted skins that lack AP-2α and AP-2γ, it is tempting to speculate that suprabasal K14/K5 might be a component of a hyperproliferative feedback mechanism triggered when the terminal differentiation process is perturbed. Other major functions unveiled from our double loss of function are previously masked roles for AP-2α and AP-2γ in HF maturation and sebaceous gland differentiation. HFs were dramatically altered in their angling, morphology, and differentiation in AP-2 DcKO animals. In addition, expression of terminal differentiation-specific genes for HF was markedly suppressed. The degeneration of HFs into cystlike structures was accompanied by elevated levels of apoptosis, suggesting that AP-2α and AP-2γ also likely operate at the transition between proliferation and differentiation of HF progenitors and maintain a normal HF differentiation program. One of the most striking features of skin lacking AP-2α and AP-2γ was its resemblance to skin compromised for Notch signaling through loss of RBP/J. This was true not only for epidermis, but also HFs and sebaceous glands, all known to be regulated by Notch signaling (Okuyama et al., 2004; Pan et al., 2004; Blanpain and Fuchs, 2006). Moreover, the parallels extended to the gross hyperproliferation and premalignant states observed postnatally (Nicolas et al., 2003; Blanpain et al., 2006; Lee et al., 2007). Although no such connections between AP-2 and Notch have previously been described in vertebrates, our results were intriguing in light of genetic studies that placed the single Drosophila melanogaster AP-2 gene downstream of Notch signaling in joint and leg development (Kerber et al., 2001). Similar to what we observed in mouse skin, fly joints harboring loss- or gain-of-function mutations in either dAP-2 or Notch exhibited similar phenotypes. However, in this fly tissue, a linear pathway was suggested, based on the ability of activated Notch to induce dAP-2 expression (Kerber et al., 2001). The loss of dAP-2 did not affect epidermis (Monge et al., 2001), although it is notable that fly epidermis exists as only a single layer of cells that secrete their cuticle rather than undergo a terminal differentiation program to form a barrier to the body surface. In mouse skin, the existence of multiple AP-2 and Notch signaling pathway members seems to have added several additional and interesting layers of complexities to what appears to be an ancient regulatory mechanism. As in fly joints, where loss of dAP-2 did not perturb Notch's ability to activate its target genes (big brain and E(spl); Kerber et al., 2001), Notch signaling was still intact in AP-2 DKO mouse keratinocytes, as indicated by the ability of NICD to induce its classical target genes Hes1 and Hey1. We also observed a severalfold induction of AP-2γ by NICD expression. However, AP-2α showed little or no change in response to NICD, and neither of these AP-2 factors exhibited appreciable down-regulation when RBP/J expression was ablated in keratinocytes. Rather, the inability of Notch to elicit its full effects on epidermal terminal differentiation in mice lacking these AP-2 factors appeared to be rooted at least in part in the loss of C/EBP transcription, which in turn works concomitantly with AP-2 factors to orchestrate a complex program of gene expression necessary to produce the epidermal barrier. Although our data strongly support a parallel relationship, the slightly reduced expression of RBP/J in AP-2 DKO keratinocytes raises the possibility that cross talk does exist between AP-2 and Notch, and this could impact C/EBP as well as other downstream gene expression. Although exploration into the mechanisms underlying AP-2 and epidermal appendage formation is beyond the scope of the present study, it is intriguing that both C/EBPα and C/EBPβ display strong nuclear localization in sebocytes (Bull et al., 2002; unpublished data), and both C/EBPs and AP-2s also function in adipocyte differentiation and lipid metabolism (Jiang et al., 1998; Otto and Lane, 2005). This opens the possibility that AP-2 transcription factors and Notch signaling may also converge on C/EBPs to regulate differentiation and lipid metabolism of these lineages. In contrast, neither C/EBPα nor C/EBPβ was detected in the differentiating layers of HFs (Bull et al., 2002; unpublished data), suggesting that some other downstream targets mediate the effects of AP-2 transcription factors and Notch signaling in HF lineage differentiation. Concluding remarks Nearly two decades after their initial discovery in epidermis and the subsequent widespread occurrence of AP-2 binding sites in epidermal promoters, major functions for AP-2 factors in mammalian skin epithelium are starting to emerge. Although further layers of redundancy are likely to unravel additional interesting roles for AP-2s in skin biology, the loss of AP-2α and AP-2γ has already unmasked a hitherto unexpected link between AP-2 transcription factors and Notch signaling in a mammalian tissue. Previously only observed in Drosophila (Kerber et al., 2001), this surprising connection between Notch and AP-2 in a mammalian tissue now highlights the existence of an ancient molecular link that over evolution has been elaborated on greatly. Given the widespread involvement of both Notch signaling and AP-2 expression in many cell types and tissues, these findings merit further investigation in the future. Based on the evolutionary and/or tissue-specific differences already noted between the action of dAP-2 (Kerber et al., 2001) and mammalian AP-2α and AP-2γ (this study) and the findings that AP-2s can act as either transcriptional repressors or activators (Pfisterer et al., 2002), it is both plausible and likely that additional complexities in transcriptional activities of AP-2s and their tissue- and differentiation stage–dependent contexts will emerge as more studies are conducted. Finally, it is interesting to speculate that the mechanism underlying the hyperproliferative feedback pathway that seems to operate when the epidermal barrier is compromised may involve a precariously elevated EGFR signaling sensor that arises from differences in AP-2 levels/expression. If true, this notion would help to explain the confusing and often opposing correlations in expression levels of AP-2 family members in human cancers (Pellikainen and Kosma, 2007). Materials and methods Mice K14-Cre/AP-2αlox/lox cKO (α-cKO) mice were generated as described in Wang et al. (2006). AP-2γlox/lox mice were crossed with K14-Cre mice to generate K14-Cre/AP-2γlox/lox cKO (γ-cKO) mice (Vasioukhin et al., 1999). α-cKO and γ-cKO mice were then mated to generate K14-Cre/AP-2αlox/loxAP-2γlox/lox DcKO mice. Immunostaining and immunoblots Histology and immunofluorescence were performed as described previously (Wang et al., 2006). For immunohistochemistry, tissues were fixed in formaldehyde and then dehydrated and embedded in paraffin. Antigen unmasking was performed in Retriever 2100 for 20 min (PickCell Laboratories BV). Antibodies and dilutions used were as follows: AP-2α (mouse, 1:100; Millipore), K5 (chicken, 1:500; Fuchs Laboratory), AP-2γ (mouse, 1:100; Millipore), K1 (rabbit, 1:250; Fuchs Laboratory), Involucrin (rabbit, 1:200; Covance), Filaggrin (rabbit, 1:250; Covance), BrdU (rat, 1:100; Abcam), active caspase 3 (rabbit, 1:500; R&D Systems), K8 (rat, 1:1,000; Fuchs Laboratory), K6 (rabbit, 1:1,000; Fuchs Laboratory), C/EBPα (rabbit, 1:250; Santa Cruz Biotechnology, Inc.), C/EBPβ (rabbit, 1:250; Santa Cruz Biotechnology, Inc.), integrin β4 chain (rat, 1:250; BD Biosciences), Loricrin (rabbit, 1:250; Covance), K18 (rabbit, 1:50, Fuchs Laboratory), phospho-Akt (rabbit, 1:250; Cell Signaling Technology), Gata3 (mouse, 1:50; Santa Cruz Biotechnology, Inc.), AE15 (mouse, 1:50; Fuchs Laboratory), and AE13 (mouse, 1:50; Fuchs Laboratory). Secondary antibodies coupled to FITC, Alexa 488, or Texas red were obtained from Jackson ImmunoResearch Laboratories. Nuclei were labeled by DAPI for immunofluorescence. For immunoblots, total cell lysates were prepared in lysis buffer. Samples were separated on 12% SDS-PAGE gels, transferred to nitrocellulose, and blotted overnight with the indicated antibodies. Real-time PCR RNAs were isolated using RNeasy Plus Mini kit (QIAGEN). RNA quality and concentration were measured by spectrophotometer (NanoDrop). Equal RNA amounts were added to reverse transcription reaction mix (Invitrogen) with oligo-dT(12) as primer. All PCR test primers flanked exon–intron boundaries to avoid misinterpretation from genomic contamination. Real-time PCRs of RNA (i.e., not reverse transcribed) were used as negative controls. Real-time PCR was conducted with a LightCycler system (LightCycler 480; Roche). Reactions were performed using the indicated primers and template mixed with the LightCycler DNA master SYBR Green kit and run for 45 cycles. Specificity of the reactions was determined by subsequent melting curve analysis. LightCycler analysis software was used to remove background fluorescence (noise band). The number of cycles needed to reach the crossing point for each sample was used to calculate the amount of each product using the 2−ΔΔCP method. Levels of PCR product were expressed as a function of GAPDH. Primer sequences are as follows: K1F, 5′-GACACCACAACCCGGACCCAAAACTTAGAC-3′; K1R, 5′-ATACTGGGCCTTGACTTCCGAGATGATG-3′; K10F, 5′-GCCAGAACGCCGAGTACCAACAAC-3′; K10R, 5′-GTCACCTCCTCAATAATCGTCCTG-3′; FilF, 5′-GTGGCCAACAGAGAATGAG-3′; FilR, 5′-ATGATGCCCAGAACTATGTGAC-3′; Tgm1F, 5′-GCGGAGGGCTGTGGAGAAGG-3′; Tgm1R, 5′-GGGTGCGCAAACGGAAGGTG-3′; Tgm3F, 5′-GCTTGGGGGTTCGCTCTCG-3′; Tgm3R, 5′-CTGCCTACTGCCTTGGTGCTGAT-3′; K8F, 5′-TGGAGGGGGAGGAGAGCAG-3′; K8R, 5′-AAGGTTGGCCAGAGGATTAGG-3′; K6F, 5′-AGCCACCGTGGCTACAGTGC-3′; K6R, 5′- CTGGTTGATGGTGACCTCTT-3′; C/EBPαF, 5′-AGCTGGCCCCGTGAGAAAAATGA-3′; C/EBPαR, 5′-AATGGTCCCCGTGTCCTCCTATCC-3′; C/EBPβF, 5′-CTATTTCTATGAGAAAAGAGGCGTATGTAT-3′; C/EBPβR, 5′-ATTCTCCCAAAAAAGTTTATTAAAATGTCT-3′; AP-2αF, 5′-TGCGGAGAGCGAAGTC-3′; AP-2αR, 5′-GGCCTCGGTGAGATAGTTCT-3′; AP-2γF, 5′-GCCACGCGGAAGAGTATGT-3′; AP-2γR, 5′-CCCGGGTTCATGTAGGACTTA-3′; RBP/JF, 5′-AATTTCCACGCCAGTTCACAA-3′; RBP/JR, 5′-GTCCCCGCCGCCATTCA-3′. Electron microscopy Tissues were fixed for >1 h in 2% glutaraldehyde, 4% formaldehyde, and 2 mM CaCl2 in 0.05 M sodium cacodylate buffer, and then processed for epon embedding. Samples were visualized with a transmission electron microscope (Tecnai 12-G2; FEI Company). Barrier function assay Barrier assays were performed as described previously (Kaufman et al., 2003). In the absence of a functional epidermal barrier, the X-gal solution penetrates the skin, and an endogenous β-galactosidase–like activity catalyzes production of a blue precipitate. FACS analyses FACS analyses of keratinocytes from embryonic mouse back skin were performed as described previously (Blanpain et al., 2006). Cell cycle analyses were performed using the BrdU Flow kit (BD Biosciences). FACS purification of transduced keratinocytes was performed on a FACS Vantage SE system equipped with FACS DiVa software (BD Biosciences). Cells were gated for single events and viability, and then sorted according to their GFP expression. Cell culture and reporter assays Mouse keratinocytes were grown in E medium (15% serum and 50 μM CaCl2), and calcium switch experiments were performed by adding calcium chloride at a 1.5-mM final concentration (Wang et al., 2006). Retroviral transfection experiments were performed on cells grown in E-low Ca2+ media, and cultures were analyzed for gene expression 36 h later. For colony-forming assays, equal numbers of keratinocytes isolated from postnatal day 0 (P0) back skin were serial diluted by 5× and plated onto consecutive wells of 6-well plates seeded with mitomycin-treated 3T3 fibroblasts in rich media. After 14 d, colony number and size were visualized with 1% rhodamine B (Sigma-Aldrich). Reporter assays were performed as described previously (Wang et al., 2006). We used the dual-glo luciferase assay kit to monitor both the firefly luciferase activity driven by the C/EBPα promoter plus 5′-UTR sequence and Renilla luciferase under the control of a constitutive promoter to control for transfection efficiency. Results were expressed as a ratio of firefly to Renilla luciferase activities. Plasmids and constructs The C/EBPα reporter construct was a gift from D. Lane (Johns Hopkins University, Baltimore, MD). Retroviral murine stem cell virus construct encoding AP-2α was described in Wang et al. (2006). Retroviral (murine stem cell virus) construct encoding C/EBPα was obtained by inserting C/EBPα cDNA digested out of construct #10470123 (American Type Culture Collection) into murine stem cell virus. Retroviral construct encoding C/EBPβ was a gift from J. Friedman (The Rockefeller University, New York, NY). The lentiviral construct encoding a shRNA targeting RBP/J was obtained from Sigma-Aldrich. Image acquisition and manipulation The histology and immunofluorescent images were taken by an Axioskop 2 mot plus microscope (Carl Zeiss, Inc.). The objectives used were 20×/0.5 Plan-NEOFLUAR ∞/0.17 and 40×/1.3 oil Plan-NEOFLUAR ∞/0.17 (Carl Zeiss, Inc.). The images were taken at room temperature in antifade as an imaging medium for immunofluorescent images and 80% glycerol for hematoxylin and eosin images. The fluorochromes used were FITC, rhodamine red X, and DAPI. A camera (SPOT RT slider; Diagnostic Instruments, Inc.) and Metamorph 6 software (MDS Analytical Technologies) were used to acquire the pictures. Photoshop 6.0 (Adobe) software was used for contrast and brightness adjustment. The Immunoblot images were acquired with an Alphaimager (Alpha Innotech) and Photoshop 6.0 was used for contrast and brightness adjustment. Online supplemental material Fig. S1 shows that conditional loss of AP-2α and AP-2γ suppresses terminal differentiation in E18.5 and P0 epidermis. Fig. S2 shows absence of K18, but ectopic K6 expression in E18.5 and P0 DcKO epidermis. Fig. S3 shows diminished C/EBPα and C/EBPβ immunostaining in E17.5 DcKO but not in α-cKO or γ-cKO epidermis. Fig. S4 shows that AP-2α and AP-2γ are necessary for terminal differentiation within HFs. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.200804030/DC1. [Supplemental Material Index]
Acknowledgments We are grateful for the C/EBPα reporter construct from Daniel Lane and the C/EBPβ retroviral expression vector from Jeffrey Friedman. We thank Lisa Polak and Nicole Stokes for their expert assistance in skin engraftments; Svetlana Mazel for flow cytometry; and Valerie Horsley, Haiying Zhang, and other members of the Fuchs Laboratory for their thoughtful suggestions and advice. E. Fuchs is an Investigator of the Howard Hughes Medical Institute. This work was supported by the National Institutes of Health grants NIH-RO1-AR31737 (E. Fuchs) and DE12728 (T. Williams). Notes Abbreviations used in this paper: 1°MK, primary mouse epidermal keratinocytes; C/EBP, CCAAT/enhancer binding protein; cKO, conditional knockout; DcKO, double cKO; DKO, double knockout; DP, dermal papilla; E, embryonic day; EGFR, EGF receptor; HF, hair follicle; NICD, Notch intracellular domain; P0, postnatal day 0; shRNA, short hairpin RNA; WT, wild type. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||
Development. 1994 Sep; 120(9):2369-83.
[Development. 1994]Cell. 1980 Apr; 19(4):1033-42.
[Cell. 1980]J Biol Chem. 1987 Nov 15; 262(32):15643-8.
[J Biol Chem. 1987]J Clin Invest. 2006 May; 116(5):1150-8.
[J Clin Invest. 2006]Annu Rev Cell Dev Biol. 2006; 22():339-73.
[Annu Rev Cell Dev Biol. 2006]Trends Cell Biol. 2007 Jul; 17(7):318-24.
[Trends Cell Biol. 2007]Dev Biol. 1999 Dec 1; 216(1):164-81.
[Dev Biol. 1999]Mol Cell Biol. 1999 Oct; 19(10):7181-90.
[Mol Cell Biol. 1999]Curr Opin Genet Dev. 2004 Oct; 14(5):485-91.
[Curr Opin Genet Dev. 2004]Genes Dev. 1990 Nov; 4(11):1985-98.
[Genes Dev. 1990]Development. 1991 Sep; 113(1):283-93.
[Development. 1991]Development. 1994 Sep; 120(9):2369-83.
[Development. 1994]Nat Genet. 1997 Jan; 15(1):78-82.
[Nat Genet. 1997]Dev Biol. 1999 Dec 1; 216(1):164-81.
[Dev Biol. 1999]Dev Biol. 2002 May 1; 245(1):136-44.
[Dev Biol. 2002]J Cell Biol. 2006 Jan 30; 172(3):409-21.
[J Cell Biol. 2006]Nature. 1996 May 16; 381(6579):238-41.
[Nature. 1996]Dev Biol. 2008 May 1; 317(1):187-95.
[Dev Biol. 2008]J Cell Biol. 2006 Jan 30; 172(3):409-21.
[J Cell Biol. 2006]Dev Biol. 2008 May 1; 317(1):187-95.
[Dev Biol. 2008]Dev Biol. 2004 Mar 1; 267(1):72-92.
[Dev Biol. 2004]J Cell Biol. 2006 Jan 30; 172(3):409-21.
[J Cell Biol. 2006]J Cell Biol. 2006 Jan 30; 172(3):409-21.
[J Cell Biol. 2006]J Cell Biol. 2006 Jan 30; 172(3):409-21.
[J Cell Biol. 2006]Nature. 2007 Feb 22; 445(7130):834-42.
[Nature. 2007]Dev Biol. 1999 Dec 1; 216(1):164-81.
[Dev Biol. 1999]Mol Cell Biol. 1999 Oct; 19(10):7181-90.
[Mol Cell Biol. 1999]Birth Defects Res C Embryo Today. 2005 Dec; 75(4):314-29.
[Birth Defects Res C Embryo Today. 2005]Mol Cell Biol. 1997 Mar; 17(3):1274-80.
[Mol Cell Biol. 1997]Genes Dev. 2000 Aug 1; 14(15):1920-32.
[Genes Dev. 2000]Development. 1991 Sep; 113(1):283-93.
[Development. 1991]Proc Natl Acad Sci U S A. 2003 Jan 21; 100(2):532-7.
[Proc Natl Acad Sci U S A. 2003]Dev Growth Differ. 2005 Aug; 47(6):403-13.
[Dev Growth Differ. 2005]Dev Biol. 1999 Dec 1; 216(1):164-81.
[Dev Biol. 1999]Genes Dev. 2006 Nov 1; 20(21):3022-35.
[Genes Dev. 2006]Curr Biol. 2000 May 4; 10(9):491-500.
[Curr Biol. 2000]Dev Cell. 2004 Apr; 6(4):551-62.
[Dev Cell. 2004]J Invest Dermatol. 2008 Apr; 128(4):825-32.
[J Invest Dermatol. 2008]Science. 1999 Apr 30; 284(5415):770-6.
[Science. 1999]J Cell Physiol. 2003 Mar; 194(3):237-55.
[J Cell Physiol. 2003]Development. 2004 Mar; 131(5):965-73.
[Development. 2004]Dev Cell. 2004 Apr; 6(4):551-62.
[Dev Cell. 2004]Genes Dev. 2006 Nov 1; 20(21):3022-35.
[Genes Dev. 2006]Genes Dev. 2006 Nov 1; 20(21):3022-35.
[Genes Dev. 2006]Nat Genet. 2003 Mar; 33(3):416-21.
[Nat Genet. 2003]Dev Cell. 2004 Nov; 7(5):731-43.
[Dev Cell. 2004]Development. 2007 Aug; 134(15):2795-806.
[Development. 2007]Cell. 2004 Sep 3; 118(5):635-48.
[Cell. 2004]Proc Natl Acad Sci U S A. 2005 Oct 11; 102(41):14677-82.
[Proc Natl Acad Sci U S A. 2005]J Cell Biol. 2006 Jan 30; 172(3):409-21.
[J Cell Biol. 2006]Nat Rev Cancer. 2006 Jan; 6(1):11-23.
[Nat Rev Cancer. 2006]Proc Natl Acad Sci U S A. 1999 Jul 20; 96(15):8551-6.
[Proc Natl Acad Sci U S A. 1999]Genes Dev. 1990 Nov; 4(11):1985-98.
[Genes Dev. 1990]Development. 1994 Sep; 120(9):2369-83.
[Development. 1994]Mol Cell Biol. 2000 Apr; 20(7):2543-55.
[Mol Cell Biol. 2000]Dev Cell. 2004 Apr; 6(4):551-62.
[Dev Cell. 2004]Dev Cell. 2004 Nov; 7(5):731-43.
[Dev Cell. 2004]Annu Rev Cell Dev Biol. 2006; 22():339-73.
[Annu Rev Cell Dev Biol. 2006]Nat Genet. 2003 Mar; 33(3):416-21.
[Nat Genet. 2003]Genes Dev. 2006 Nov 1; 20(21):3022-35.
[Genes Dev. 2006]Development. 2001 Apr; 128(8):1231-8.
[Development. 2001]Development. 2001 Apr; 128(8):1239-52.
[Development. 2001]Development. 2001 Apr; 128(8):1231-8.
[Development. 2001]J Invest Dermatol. 2002 Jan; 118(1):17-24.
[J Invest Dermatol. 2002]Proc Natl Acad Sci U S A. 1998 Mar 31; 95(7):3467-71.
[Proc Natl Acad Sci U S A. 1998]Crit Rev Biochem Mol Biol. 2005 Jul-Aug; 40(4):229-42.
[Crit Rev Biochem Mol Biol. 2005]Development. 2001 Apr; 128(8):1231-8.
[Development. 2001]Development. 2001 Apr; 128(8):1231-8.
[Development. 2001]J Biol Chem. 2002 Feb 22; 277(8):6637-44.
[J Biol Chem. 2002]Int J Cancer. 2007 May 15; 120(10):2061-7.
[Int J Cancer. 2007]J Cell Biol. 2006 Jan 30; 172(3):409-21.
[J Cell Biol. 2006]Proc Natl Acad Sci U S A. 1999 Jul 20; 96(15):8551-6.
[Proc Natl Acad Sci U S A. 1999]J Cell Biol. 2006 Jan 30; 172(3):409-21.
[J Cell Biol. 2006]Genes Dev. 2003 Sep 1; 17(17):2108-22.
[Genes Dev. 2003]Genes Dev. 2006 Nov 1; 20(21):3022-35.
[Genes Dev. 2006]J Cell Biol. 2006 Jan 30; 172(3):409-21.
[J Cell Biol. 2006]J Cell Biol. 2006 Jan 30; 172(3):409-21.
[J Cell Biol. 2006]J Cell Biol. 2006 Jan 30; 172(3):409-21.
[J Cell Biol. 2006]